Health Care · Pharmaceutical Preparations

CATX Perspective Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 728387145 filings
Russell 2000

CATX at a glance

Perspective Therapeutics, Inc. (CATX, SEC CIK 728387) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Perspective Therapeutics, Inc. (CATX) shares worth $102.3 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Williamson Robert F III on November 18, 2026 of 15,000 shares at $0.80 per share.
  • In the last 90 days, CATX insiders reported 10 open-market purchases ($175K) and 7 open-market sales ($1.6M) on Form 4, a net sale of $1.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
10 buys · 7 sells
Net −$1.4M
13F holders
21 funds
$102.3M · −3 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02 · Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Grant revenue $0.2 million lower YoY; operating loss $34.3 million vs $27.9 million
  • R&D expenses $26.1 million, up $5.8 million YoY, driven by clinical and manufacturing investment
  • VMT-α-NET strongest program: Cohort 3 disease control 95%, versus Cohort 2 at 89%
  • Cash, equivalents and short-term investments $201.7 million; operating cash use $83.5 million through nine months
  • Expenses expected to rise; funding sufficient into 2028, with additional capital likely required before profitability

Risk Factors

  • No material changes to 2025 Form 10-K risk factors
  • Carried-forward risk: unidentified or presently unknown risks could materially adversely affect business
  • Market risk: securities price could decline significantly or permanently
  • General business risk: identified risks could materially adversely affect financial condition and results of operations

AI summary of the CATX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Q3 2026 results for quarter ended September 30, 2026
  • Recent business highlights accompany financial results, with details in Exhibit 99.1

Item 8.01: Other Events

  • Updated corporate presentation posted November 9, 2026, providing investors with the company’s latest strategic and business overview
  • Presentation filed as Exhibit 99.2, requiring review for updated pipeline, clinical, financing, or corporate developments

Item EX-99.2: Item EX-99.2

  • Investor presentation outlines three independent clinical-stage radiopharmaceutical programs, each targeting data in 2027
  • Pipeline targets neuroendocrine tumors, melanoma, advanced solid tumors and selected medullary thyroid cancers

Item EX-99.1: Item EX-99.1

  • 3Q 2026 results: net loss $32.4M, or $0.27 per share, versus $26.0M and $0.35 in 3Q 2025
  • Cash, equivalents and short-term investments $202M at September 30, 2026, funding planned milestones and investments into 2028
Filed Nov 6, 2026Full analysis →

Item 8.01: Other Events

  • New Phase 1/2a VMT-α-NET data and analyses presented at NANETS 2026
  • Program targets unresectable or metastatic SSTR2-expressing neuroendocrine tumors

Item EX-99.1: Item EX-99.1

  • Bamzireotide showed 75% 18-month PFS and 95% disease control across 57 SSTR2-positive GEP-NET patients
  • Objective response rate reached 39% in the 57-patient enrichment subgroup, supporting potential registration-study patient selection
Filed Nov 6, 2026Full analysis →

Item 8.01: Other Events

  • Updated interim Phase 1/2a results for VMT01 melanoma diagnosis and treatment presented at SITC’s 41st Annual Meeting
  • Trial targets unresectable or metastatic melanoma patients with melanocortin 1 receptor tumor expression

Item EX-99.2: Item EX-99.2

  • Phase I/IIa monotherapy data support continued development of [212Pb]VMT01 in previously treated metastatic melanoma
  • No dose-limiting toxicities among 20 patients, with grade ≥3 and serious TEAEs each affecting 5 participants (25%)

Item EX-99.1: Item EX-99.1

  • Phase 1/2a VMT01 melanoma data: 75% disease control at the 3.0 mCi focus dose
  • Two of eight patients achieved partial responses, with one ongoing approximately 40 weeks after first treatment

AI summaries of CATX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CATX

Don't miss the next CATX filing

  • Alerts as it files. A push when CATX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CATX, by share count.
  • Ask anything. An AI agent that reads every CATX filing and answers with sources.

CATX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Williamson Robert F IIIBuyNov 18, 2026$0.80
Williamson Robert F IIIBuyNov 17, 2026$0.84
Morich FrankBuyNov 16, 2026$0.94
Woods Lori ABuyNov 12, 2026$0.84
Morich FrankBuyNov 12, 2026$1.00
Williamson Robert F IIIBuyNov 12, 2026$0.84
Williamson Robert F IIIBuyNov 12, 2026$0.84
Puhlmann MarkusBuyNov 12, 2026$0.84

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Gross Profit$1.4M--
Operating Income--$90.9M-$113.6M
Net Income-$46.5M-$79.3M-$103.1M
Balance Sheet
Total Assets$97.9M$341.1M$267.0M
Equity$75.2M$290.7M$207.0M
ROE-61.9%-27.3%-49.8%
Per Share
EPS-$-1.23$-1.40
Cash Flow
Operating CF-$36.9M-$18.3M-$82.5M
CapEx$1.1M$54.4M$12.7M

Source: XBRL data in Perspective Therapeutics, Inc. (CATX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CATX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CATX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202621$102.3M
Q2 202624$131.9M
Q1 202623$119.9M
Q4 202521$51.7M
Q3 202519$95.1M
Q2 202520$92.5M
Q1 202517$40.3M
Q4 202414$55.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 159 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CATX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 18, 2026--
4Nov 17, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 13, 2026--
4Nov 12, 2026--
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
8-KNov 6, 2026Analysis-
8-KNov 6, 2026Analysis-
8-KOct 23, 2026Analysis-
8-KOct 8, 2026Analysis-
8-KOct 1, 2026Analysis-
8-KSep 14, 2026Analysis-
8-KSep 8, 2026Analysis-
4Sep 8, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 3, 2026--
4Sep 2, 2026--
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
SC 13GAug 7, 2026-

Related Health Care companies

All Health Care →

CATX SEC filings: frequently asked questions

Are CATX insiders buying or selling?

In the last 90 days, Perspective Therapeutics, Inc. (CATX) officers, directors and 10% owners reported 10 open-market purchases worth $175,386 by 5 insiders and 7 open-market sales worth $1.6 million by 2 insiders on Form 4, a net sale of $1.4 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CATX stock?

As of September 30, 2026, the largest Perspective Therapeutics, Inc. (CATX) holders among the 13F filers tracked by SignalX were BlackRock ($32.5 million), Millennium Management ($17.0 million), Vanguard Capital Management LLC ($12.1 million), Citadel Advisors LLC ($10.9 million), Two Sigma Investments ($8.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did CATX report in its latest 8-K?

Perspective Therapeutics, Inc. (CATX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Press release covers Q3 2026 results for quarter ended September 30, 2026.

What are the latest CATX SEC filings?

Perspective Therapeutics, Inc. (CATX) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 19, 2026.

What is CATX's SEC CIK number?

Perspective Therapeutics, Inc. (CATX)'s SEC Central Index Key (CIK) is 728387. EDGAR lists every CATX filing under that number.

Ask anything about CATX

The research agent reads CATX's filings, financials, insider trades and 13F holders, then answers with sources.